Developer docs
API playgroundTry for free, no card

Search company profiles

NeuroPace

Full company profile

uuid0000dnw

Namestring
NeuroPace
Legal namestring
NeuroPace, Inc.
Websiteurl
neuropace.com
Company typeenum
Public
Founded yearint
1997
Descriptiontext

NeuroPace, Inc. is a Mountain View, California-based medical device company founded in 1997 and publicly traded on NASDAQ under the ticker NPCE. The company developed the RNS (Responsive Neurostimulation) System, the only FDA-approved closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The system comprises an implantable neurostimulator connected to intracranial leads that detect patient-specific EEG patterns and deliver targeted electrical stimulation to abort seizures. Clinical evidence from a three-year Post-Approval Study published in Neurology demonstrated 82% median seizure reduction across 324 patients at 32 U.S. centers, and 8,000+ patients are monitored through the FDA-cleared platform.

The RNS System is complemented by a cloud-based software platform that includes the nSight clinician portal for remote patient monitoring, the tablet-based Patient Data Management System (PDMS) for in-clinic review and device programming, and the FDA-approved ECoG Assistant AI tool for intracranial EEG analysis. NeuroPace is pursuing indication expansion into idiopathic generalized epilepsy via the NAUTILUS pivotal trial, with a PMA supplement filed in December 2025 and mid-2026 FDA approval targeted. The company is also evaluating the RNS System for Lennox-Gastaut Syndrome under an NIH-funded feasibility study.

Revenue is generated primarily from RNS System device sales recognized upon implantation and replacement, distributed through approximately 200+ Level 4 comprehensive epilepsy centers in the United States via direct field sales. FY2025 revenue reached approximately $100 million, representing 25% year-over-year growth, with Q1 2026 revenue of $22.1 million. Reimbursement improved materially effective January 1, 2026, with hospital replacement reimbursement rising 47% and physician fees increasing 43-45%. NeuroPace is exiting its non-core DIXI Medical distribution business by June 30, 2026 to focus on its pure-play RNS strategy.

Short descriptiontext

NeuroPace markets the FDA-approved RNS System, a closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The platform serves Level 4 epilepsy centers in the US and is expanding into generalized epilepsy indications and AI-driven clinical decision support tools.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromodulation devices, responsive neurostimulation, epilepsy treatment, brain stimulation implants, intracranial EEG monitoring
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Implantable Neurostimulators
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1RNS System Device Sales
TypeHardware Sales
Description

Primary revenue driver from initial implantation procedures and subsequent device replacements. Revenue recognized upon device implantation and replacement. Q1 2026 RNS System revenue of $21.7 million representing 18.5-19.5% year-over-year growth.

tradingview.com
2Medicare/Commercial Reimbursement
TypeTransaction Fee
Description

Hospital and physician reimbursement for RNS procedures. Medicare reimbursement updates effective January 1, 2026 increased physician payments by approximately 43% for initial implant and 45% for replacement procedures. Hospital replacement reimbursement rose 47% to $31,526 from $21,444.

tradingview.com
3Discontinued DIXI Distribution
TypeHardware Sales
Description

Non-core distribution business being exited by June 30, 2026. Revenue contribution from DIXI Medical excluded in non-GAAP reporting (e.g., Q1 2026 non-GAAP revenue of $22.0M excludes DIXI).

tradingview.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details2 tiers
1Hospital outpatient reimbursement for RNS System replacement procedures
ModelTransaction based/ take rateBilling cadencePer procedure
Notes

Effective January 1, 2026: Hospital Medicare reimbursement for RNS System replacement (CPT 61891) increased 47% from $21,444 to $31,526. Procedure reassigned to highest-paying neurostimulator APC level.

finance.yahoo.com
2Physician professional fees for RNS procedures
ModelTransaction based/ take rateBilling cadencePer procedure
Notes

Effective January 1, 2026: Professional payment rates increased approximately 43% (~$530) for initial implant procedures and 45% (~$260) for replacement procedures, supporting neurosurgeon adoption.

finance.yahoo.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1RNS System
Description

Brain-responsive neuromodulation device for treating drug-resistant epilepsy

neuropace.com
+3 more records
Core offering1 text field

NeuroPace develops and markets the RNS (Responsive Neurostimulation) System, the first and only FDA-approved closed-loop brain-responsive neuromodulation device, which monitors intracranial electrocorticography (ECoG) signals and delivers targeted electrical stimulation to abort seizures in adults with drug-resistant focal epilepsy. The core revenue-generating offering is the implantable neurostimulator plus NeuroPace-supplied leads and supporting clinician software, sold to Level 4 epilepsy centers and implanted by neurosurgeons. Supporting software products include the nSight cloud platform, the ECoG Assistant AI analysis tool, and the Patient Data Management System (PDMS).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 82% median seizure reduction at 3 years in drug-resistant focal epilepsy patients (Post-Approval Study, 324 patients, 32 centers)
+5 more records
Product overview1 text field

NeuroPace offers a unified epilepsy treatment platform centered on the RNS System, a brain-responsive neuromodulation device that delivers personalized, closed-loop stimulation therapy for drug-resistant focal epilepsy. The platform integrates multiple components: the RNS neurostimulator (including RNS-320 and RNS-300M models) and leads implanted in the brain; the nSight cloud-based clinician platform for remote patient monitoring and data access; the Patient Data Management System (PDMS) for in-clinic data review and device programming; and the FDA-approved ECoG Assistant AI tool for automated intracranial EEG analysis. The company is strategically shifting toward software-driven growth with its AI-powered tools, migrating clinician platforms to cloud infrastructure, while focusing on its core RNS franchise for epilepsy treatment.

Product and service1 record
1RNS System (Responsive Neurostimulation System)
Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-30
Description

Former distribution partnership for DIXI Medical products in the U.S. NeuroPace announced early termination of this non-core distribution business to focus on its pure-play RNS strategy. Exit expected by June 30, 2026.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with FDA's NEST program, funded by an FDA grant to MDIC, facilitating real-world evidence in device submissions including pediatric device approvals. NeuroPace working with NEST to navigate regulatory processes using real-world data.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

LivaNova markets VNS Therapy (vagus nerve stimulation), the other primary FDA-approved neuromodulation therapy for drug-resistant epilepsy. Most directly comparable competitor in epilepsy neuromodulation, though using open-loop stimulation versus NeuroPace's closed-loop approach.

TypeBroad incumbent
Description

Medtronic offers the Percept PC DBS system with BrainSense sensing for epilepsy and other indications. A broad incumbent in neuromodulation with deep R&D resources and global distribution, posing long-term competitive risk in closed-loop technology.

TypeBroad incumbent
Description

Boston Scientific acquired VNS Therapy from Cyberonics and markets a broad neuromodulation portfolio including spinal cord and deep brain stimulators. Large incumbent with diversified indications and global commercial reach.

TypeBroad incumbent
Description

Abbott's Neuromodulation division markets Proclaim DRG and Infinity DBS systems across multiple indications. A diversified incumbent with scale advantages in R&D, clinical evidence, and global distribution.

TypeEmerging player
Description

Inspire Medical Systems markets hypoglossal nerve stimulation for obstructive sleep apnea. Comparable as a specialized implantable neurostimulator company that scaled from a narrow indication, illustrating the growth template NeuroPace could follow.

6Axonics
TypeEmerging player
Description

Axonics markets sacral neuromodulation systems for incontinence and overactive bladder. Comparable as a smaller, focused implantable neurostimulator company pursuing indication expansion in adjacent therapeutic areas.

TypeEmerging player
Description

Nevro markets HF10 high-frequency spinal cord stimulation for chronic pain. Comparable as a specialized neuromodulation company with proprietary stimulation technology competing against incumbents in a defined clinical market.

TypeEmerging player
Description

electroCore markets gammaCore non-invasive vagus nerve stimulation for migraine and cluster headache. Comparable as a neuromodulation company pursuing adjacent neurological indications with differentiated delivery modality.

TypeEmerging player
Description

Saluda Medical is developing Evoke closed-loop spinal cord stimulation for chronic pain. Comparable as a closed-loop neuromodulation technology developer pursuing a different indication with similar responsive-stimulation architectural approach.

TypeOthers
Description

Cirtec Medical is a contract manufacturer specializing in neuromodulation and active implantable devices. Adjacent ecosystem participant providing manufacturing services to NeuroPace and its peer neuromodulation OEMs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuroPace

Implantable Neurostimulatorsneuropace.com

NeuroPace markets the FDA-approved RNS System, a closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The platform serves Level 4 epilepsy centers in the US and is expanding into generalized epilepsy indications and AI-driven clinical decision support tools.

What NeuroPace does

NeuroPace, Inc. is a Mountain View, California-based medical device company founded in 1997 and publicly traded on NASDAQ under the ticker NPCE. The company developed the RNS (Responsive Neurostimulation) System, the only FDA-approved closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The system comprises an implantable neurostimulator connected to intracranial leads that detect patient-specific EEG patterns and deliver targeted electrical stimulation to abort seizures. Clinical evidence from a three-year Post-Approval Study published in Neurology demonstrated 82% median seizure reduction across 324 patients at 32 U.S. centers, and 8,000+ patients are monitored through the FDA-cleared platform.

The RNS System is complemented by a cloud-based software platform that includes the nSight clinician portal for remote patient monitoring, the tablet-based Patient Data Management System (PDMS) for in-clinic review and device programming, and the FDA-approved ECoG Assistant AI tool for intracranial EEG analysis. NeuroPace is pursuing indication expansion into idiopathic generalized epilepsy via the NAUTILUS pivotal trial, with a PMA supplement filed in December 2025 and mid-2026 FDA approval targeted. The company is also evaluating the RNS System for Lennox-Gastaut Syndrome under an NIH-funded feasibility study.

Revenue is generated primarily from RNS System device sales recognized upon implantation and replacement, distributed through approximately 200+ Level 4 comprehensive epilepsy centers in the United States via direct field sales. FY2025 revenue reached approximately $100 million, representing 25% year-over-year growth, with Q1 2026 revenue of $22.1 million. Reimbursement improved materially effective January 1, 2026, with hospital replacement reimbursement rising 47% and physician fees increasing 43-45%. NeuroPace is exiting its non-core DIXI Medical distribution business by June 30, 2026 to focus on its pure-play RNS strategy.

NeuroPace firmographics

Firmographics
Name
NeuroPace
Legal name
NeuroPace, Inc.
Website
https://neuropace.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
101–250 employees
Short description
NeuroPace markets the FDA-approved RNS System, a closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. The platform serves Level 4 epilepsy centers in the US and is expanding into generalized epilepsy indications and AI-driven clinical decision support tools.
Ownership category
akta.pro rank

NeuroPace industry classification

Industry
Product category
Implantable Neurostimulators
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Neuromodulation devices
  • Responsive neurostimulation
  • Epilepsy treatment
  • Brain stimulation implants
  • Intracranial EEG monitoring

Where NeuroPace is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuroPace business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. RNS System Device Sales: Primary revenue driver from initial implantation procedures and subsequent device replacements. Revenue recognized upon device implantation and replacement. Q1 2026 RNS System revenue of $21.7 million representing 18.5-19.5% year-over-year growth.
  2. Medicare/Commercial Reimbursement: Hospital and physician reimbursement for RNS procedures. Medicare reimbursement updates effective January 1, 2026 increased physician payments by approximately 43% for initial implant and 45% for replacement procedures. Hospital replacement reimbursement rose 47% to $31,526 from $21,444.
  3. Discontinued DIXI Distribution: Non-core distribution business being exited by June 30, 2026. Revenue contribution from DIXI Medical excluded in non-GAAP reporting (e.g., Q1 2026 non-GAAP revenue of $22.0M excludes DIXI).

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePer procedureHospital outpatient reimbursement for RNS System replacement procedures
Transaction based/ take ratePer procedurePhysician professional fees for RNS procedures

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

NeuroPace product offering

Product offering

Core offering

NeuroPace develops and markets the RNS (Responsive Neurostimulation) System, the first and only FDA-approved closed-loop brain-responsive neuromodulation device, which monitors intracranial electrocorticography (ECoG) signals and delivers targeted electrical stimulation to abort seizures in adults with drug-resistant focal epilepsy. The core revenue-generating offering is the implantable neurostimulator plus NeuroPace-supplied leads and supporting clinician software, sold to Level 4 epilepsy centers and implanted by neurosurgeons. Supporting software products include the nSight cloud platform, the ECoG Assistant AI analysis tool, and the Patient Data Management System (PDMS).

Product overview

NeuroPace offers a unified epilepsy treatment platform centered on the RNS System, a brain-responsive neuromodulation device that delivers personalized, closed-loop stimulation therapy for drug-resistant focal epilepsy. The platform integrates multiple components: the RNS neurostimulator (including RNS-320 and RNS-300M models) and leads implanted in the brain; the nSight cloud-based clinician platform for remote patient monitoring and data access; the Patient Data Management System (PDMS) for in-clinic data review and device programming; and the FDA-approved ECoG Assistant AI tool for automated intracranial EEG analysis. The company is strategically shifting toward software-driven growth with its AI-powered tools, migrating clinician platforms to cloud infrastructure, while focusing on its core RNS franchise for epilepsy treatment.

Differentiator

Problem solved

Functional benefit

Brands

  • RNS System: Brain-responsive neuromodulation device for treating drug-resistant epilepsy
  • ECoG Assistant
  • nSight Platform
  • PDMS

Products and services

  • RNS System (Responsive Neurostimulation System)

Quantifiable outcome

  • 82% median seizure reduction at 3 years in drug-resistant focal epilepsy patients (Post-Approval Study, 324 patients, 32 centers)
  • +5 more outcomes

Companies that use NeuroPace

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles1 record

NeuroPace technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

NeuroPace partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • DIXI MedicalminorChannel Partner/ Reseller/ Distributor · 30 June 2026Former distribution partnership for DIXI Medical products in the U.S. NeuroPace announced early termination of this non-core distribution business to focus on its pure-play RNS strategy. Exit expected by June 30, 2026.
  • FDA (NEST - National Evaluation System for Health Technology)coreStrategic or Co-development PartnerCollaboration with FDA's NEST program, funded by an FDA grant to MDIC, facilitating real-world evidence in device submissions including pediatric device approvals. NeuroPace working with NEST to navigate regulatory processes using real-world data.

Scale indicators16 records

Recent moves8 records

Expansion highlights5 records

NeuroPace competitors and assessment

Company assessment

Direct peers

  • LivaNova: LivaNova markets VNS Therapy (vagus nerve stimulation), the other primary FDA-approved neuromodulation therapy for drug-resistant epilepsy. Most directly comparable competitor in epilepsy neuromodulation, though using open-loop stimulation versus NeuroPace's closed-loop approach.

Broad incumbents

  • Medtronic: Medtronic offers the Percept PC DBS system with BrainSense sensing for epilepsy and other indications. A broad incumbent in neuromodulation with deep R&D resources and global distribution, posing long-term competitive risk in closed-loop technology.
  • Boston Scientific: Boston Scientific acquired VNS Therapy from Cyberonics and markets a broad neuromodulation portfolio including spinal cord and deep brain stimulators. Large incumbent with diversified indications and global commercial reach.
  • Abbott: Abbott's Neuromodulation division markets Proclaim DRG and Infinity DBS systems across multiple indications. A diversified incumbent with scale advantages in R&D, clinical evidence, and global distribution.

Emerging players

  • Inspire Medical Systems: Inspire Medical Systems markets hypoglossal nerve stimulation for obstructive sleep apnea. Comparable as a specialized implantable neurostimulator company that scaled from a narrow indication, illustrating the growth template NeuroPace could follow.
  • Axonics: Axonics markets sacral neuromodulation systems for incontinence and overactive bladder. Comparable as a smaller, focused implantable neurostimulator company pursuing indication expansion in adjacent therapeutic areas.
  • Nevro: Nevro markets HF10 high-frequency spinal cord stimulation for chronic pain. Comparable as a specialized neuromodulation company with proprietary stimulation technology competing against incumbents in a defined clinical market.
  • electroCore: electroCore markets gammaCore non-invasive vagus nerve stimulation for migraine and cluster headache. Comparable as a neuromodulation company pursuing adjacent neurological indications with differentiated delivery modality.
  • Saluda Medical: Saluda Medical is developing Evoke closed-loop spinal cord stimulation for chronic pain. Comparable as a closed-loop neuromodulation technology developer pursuing a different indication with similar responsive-stimulation architectural approach.

Others

  • Cirtec Medical: Cirtec Medical is a contract manufacturer specializing in neuromodulation and active implantable devices. Adjacent ecosystem participant providing manufacturing services to NeuroPace and its peer neuromodulation OEMs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

NeuroPace social profiles

Digital presence

NeuroPace financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuroPace leadership team

Management profile

Number of profiles

Profiles13 records

NeuroPace funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuroPace M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroPace

What does NeuroPace do?

NeuroPace develops and markets the RNS (Responsive Neurostimulation) System, the first and only FDA-approved closed-loop brain-responsive neuromodulation device, which monitors intracranial electrocorticography (ECoG) signals and delivers targeted electrical stimulation to abort seizures in adults with drug-resistant focal epilepsy. The core revenue-generating offering is the implantable neurostimulator plus NeuroPace-supplied leads and supporting clinician software, sold to Level 4 epilepsy centers and implanted by neurosurgeons. Supporting software products include the nSight cloud platform, the ECoG Assistant AI analysis tool, and the Patient Data Management System (PDMS).

Is NeuroPace a public or private company?

NeuroPace is a public company. It is classified as public and is currently operating.

When was NeuroPace founded?

NeuroPace was founded in 1997. It employs 101 to 250 people.

Where is NeuroPace based?

NeuroPace is headquartered in Mountain View, United States, in the North America region.

How does NeuroPace make money?

Three revenue lines are on record. RNS System Device Sales are the primary driver. The others are medicare/Commercial Reimbursement and discontinued DIXI Distribution.

Who are NeuroPace's main competitors?

LivaNova is listed as a direct peer. Broad incumbents are Medtronic, Boston Scientific and Abbott. Emerging players are Inspire Medical Systems, Axonics, Nevro, electroCore and Saluda Medical. Cirtec Medical is listed as an others.

Does NeuroPace have an API?

No public API is recorded for NeuroPace.

What industry is NeuroPace in?

NeuroPace's product category is Implantable Neurostimulators. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageNEUROPACE, INC. INVESTIGATION: NPCE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsKirby McInerney LLP is investigating potential securities law violations against NeuroPace, Inc. The investigation follows Q3 2026 results showing revenue of $23.1 million, a 1.1% year-over-year decline, and a cut in full-year guidance to $91-92 million. Share price fell 37.1% to $7.56 on November 13, 2026.The future of tradingNPCE Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into NeuroPace, Inc. (NPCE) for Potential Securities FraudLevi & Korsinsky notified investors of an investigation into NeuroPace, Inc. for potential securities fraud. The investigation concerns whether the company adequately disclosed sales-force restructuring and customer disruptions ahead of its Q3 financial reset. NeuroPace's shares fell over 37% after reporting Q3 revenue of $23.1 million, below consensus.PR NewswireNPCE SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving NeuroPaceNeuroPace reported Q3 revenue of $23.1 million, down 1.1% year over year, and cut its 2026 revenue guidance by about $9 million. The company's stock fell roughly 37% on November 13, 2026. A securities investigation is pending, and investors who lost money may be eligible to seek recovery.Defense WorldNeuroPace (NASDAQ:NPCE) Price Target Cut to $12.00 by Analysts at HC WainwrightHC Wainwright cut its price target on NeuroPace from $20.00 to $12.00, keeping a buy rating. Other analysts have mixed ratings, with an average target of $13.11. The stock opened at $7.97, with institutional ownership at 78.83%.TradingViewMizuho maintains NeuroPace at Outperform, lowers price target to $12 from $22Mizuho maintained NeuroPace at Outperform and cut its price target to $12 from $22, a 45.5% drop. The target implies 58.7% upside from the Nov 13 close of $7.56. Recent analyst price targets range from $7 to $14.TradingViewHC Wainwright & Co. maintains NeuroPace at Buy, lowers price target to $12 from $20HC Wainwright & Co. maintained NeuroPace at Buy and lowered its price target to $12 from $20, a 40% cut. The target implies 58.7% upside from the Nov 13 close of $7.56. Recent analyst price targets range from $7 to $14.Simply Wall StThings Look Grim For NeuroPace, Inc. (NASDAQ:NPCE) After Today's DowngradeAnalysts downgraded NeuroPace, cutting 2027 revenue forecasts to $109m from $122m and raising loss-per-share estimates to $0.44 from $0.26. The consensus price target fell 29% to $14.11, and revenue growth is expected to slow to 1.9% annually, below the industry's 7.5%.MarketWatchNeuroPace Falls on Lowered Full-Year Guidance Amid Account IssuesNeuroPace shares fell 52% to $5.83 after the company lowered its full-year revenue guidance to $91-92 million, down from $99.5-101.5 million. Third-quarter revenue dropped to $23.1 million, below the prior year's $23.4 million, and the company posted a $3.3 million loss.TradingViewKeybanc maintains NeuroPace at Overweight, lowers price target to $14 from $18Keybanc maintained NeuroPace at Overweight and lowered its price target to $14 from $18, a 22.2% decrease. The target implies an upside of 16.5% from the Nov 12 close of $12.02.TradingViewLeerink Partners downgrades NeuroPace to Market Perform from Outperform, sets price target at $7Leerink Partners downgraded NeuroPace to Market Perform from Outperform and set a price target of $7. The target implies a 41.8% downside from the Nov 12 close of $12.02.